Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa
| Autor: | Gregory L. Ehle, Sean R. McMahon, Heidi S. Taatjes-Sommer, Sean Meagher, David J. Schneider, Sreedivya Chava |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Blood Platelets
medicine.medical_specialty Myocardial Infarction 030204 cardiovascular system & hematology Risk Assessment Cohort Studies 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine Medicine Humans Platelet 030212 general & internal medicine Myocardial infarction Mortality Stroke Proportional Hazards Models Aspirin Proportional hazards model business.industry Incidence Receptors IgG medicine.disease Flow Cytometry Cardiovascular Diseases Cohort Cardiology Purinergic P2Y Receptor Antagonists Drug Therapy Combination Cardiology and Cardiovascular Medicine Risk assessment business Platelet Aggregation Inhibitors medicine.drug Cohort study Follow-Up Studies |
| Zdroj: | The American journal of cardiology. 125(5) |
| ISSN: | 1879-1913 |
| Popis: | Platelet expression of FcγRIIa was quantified after myocardial infarction (MI) and we found that patients with high platelet FcγRIIa expression (>11,000/platelet) had a fourfold greater risk of subsequent MI, stroke, and death. This analysis of the original cohort of 197 patients was designed to determine whether platelet expression of FcγRIIa could be used in combination with clinical risk scores (GRACE [Global Registry of Acute Coronary Events] and DAPT [Dual Antiplatelet Therapy]) to refine cardiovascular risk assessment. Platelet expression of FcγRIIa quantified with the use of flow cytometry was broadly distributed in patients stratified into high and low risk groups based on clinical risk scores. In patients identified as high risk by the GRACE score, 62% had high platelet FcγRIIa expression. Similarly, in patients identified as high risk by DAPT, 55% had high platelet FcγRIIa expression. High platelet FcγRIIa expression discriminated high and low risk cohorts in patients with high cardiovascular risk defined by either the GRACE score (high platelet FcγRIIa 18.9% vs low platelet FcγRIIa 0%; odds ratio = 15.7, p = 0.06) or the DAPT score (high platelet FcγRIIa 15.4% vs low platelet FcγRIIa 3.7%; odds ratio = 5.6, p = 0.03) assessment. Platelet expression of FcγRIIa merits additional study to determine whether low platelet FcγRIIa expression can be used to guide early transition to aspirin monotherapy and high platelet FcγRIIa expression can be used to guide continuation of DAPT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect